Irinotecan and Temozolomide in Combination with Dasatinib and Rapamycin Versus Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma (Rist-Rnb-2011): a Multicentre, Open-Label, Randomised, Controlled, Phase 2 Trial Selim Corbacioglu , Holger Lode , Susanne Ellinger , Florian Zeman , Meinolf Suttorp , Gabriele Escherich , Konrad Bochennek , Bernd Gruhn , Peter Lang , Marius Rohde , Klaus Michael Debatin , Daniel Steinbach , Andreas Beilken , Ruth Ladenstein , Rainer Spachtholz , Peter Heiss , Dirk Hellwig , Anja Troeger , Michael Koller , Karin Menhart , Markus J. Riemenschneider , Saida Zoubaa , Silke Kietz , Marcus Jakob , Gunhild Sommer , Tilman Heise , Patrick Hundsdoerfer , Ingrid Kuehnle , Dagmar Dilloo , Stefan Schoenberger , Georg Schwabe , Irene von Luettichau , Norbert Graf , Paul-Gerhardt Schlegel , Michael Fruehwald , Norbert Jorch , Michael Paulussen , Dominik T. Schneider , Markus Metzler , Alfred Leipold , Michaela Nathrath , Thomas Imschweiler , Holger Christiansen , Irene Schmid , Roman Crazzolara , Naghmeh Niktoreh , Gunnar Cario , Joerg Faber , Martin Demmert , Florian Babor , Birgit Froehlich , Stefan Bielack , Toralf Bernig , Johann Greil , Angelika Eggert , Thorsten Simon , Juergen Foell The Lancet Oncology（2024）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
